Evaxion Biotech Earnings Call Highlights AI and Runway
TipRanks (Tue, 10-Mar 8:14 PM ET)
Evaxion: Strengthened Cash Runway and Advancing AI-Immunology Pipeline Support Buy Rating
TipRanks (Tue, 10-Mar 2:35 PM ET)
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
TipRanks (Tue, 10-Mar 8:10 AM ET)
TipRanks (Mon, 9-Mar 4:30 PM ET)
TipRanks (Mon, 9-Mar 6:30 AM ET)
Evaxion announces business update and full year 2025 financial results
Globe Newswire (Thu, 5-Mar 9:28 AM ET)
Evaxion plans to file 2025 annual report later today
Globe Newswire (Thu, 5-Mar 8:02 AM ET)
Evaxion to announce business update and full year 2025 financial results on March 5, 2026
Globe Newswire (Mon, 2-Mar 8:00 AM ET)
Evaxion expands AI-Immunology platform into autoimmune diseases
Globe Newswire (Tue, 13-Jan 8:00 AM ET)
Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
Globe Newswire (Wed, 7-Jan 8:00 AM ET)
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Evaxion A/S - American Depositary Share trades on the NASDAQ stock market under the symbol EVAX.
As of March 11, 2026, EVAX stock price climbed to $3.87 with 42,508 million shares trading.
EVAX has a beta of 1.64, meaning it tends to be more sensitive to market movements. EVAX has a correlation of 0.09 to the broad based SPY ETF.
EVAX has a market cap of $32.28 million. This is considered a Sub-Micro Cap stock.
Last quarter Evaxion A/S - American Depositary Share reported $0 in Revenue and -$.02 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.17.
In the last 3 years, EVAX traded as high as $462.50 and as low as $1.20.
EVAX has outperformed the market in the last year with a price return of +102.6% while the SPY ETF gained +23.0%. However, in the short term, EVAX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -40.0% vs -1.6% return in SPY. But in the last 2 weeks, EVAX shares have fared better than the market returning +14.8% compared to SPY -2.4%.
EVAX support price is $3.32 and resistance is $3.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVAX shares will trade within this expected range on the day.